Hostname: page-component-cd9895bd7-gvvz8 Total loading time: 0 Render date: 2024-12-22T11:10:51.433Z Has data issue: false hasContentIssue false

P0234 - Tricyclic antidepressants and Benzodiazepines abuse, among former heroin addicts currently in Methadone maintenance treatment (MMT)

Published online by Cambridge University Press:  16 April 2020

E. Peles
Affiliation:
Adelson Clinic for Drug Abuse Treatment and Research, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
S. Schreiber
Affiliation:
Adelson Clinic for Drug Abuse Treatment and Research, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel Department of Psychiatry, Tel Aviv Sourasky Medical Center, & Tel-Aviv University Sackler Faculty of Medicine, Tel Aviv, Israel
M. Adelson
Affiliation:
Adelson Clinic for Drug Abuse Treatment and Research, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background and Aims:

The tricyclic antidepressant amitriptyline was suspected to be abused among methadone maintenance treatment (MMT) patients in Israel. Given its potentially dangerous interaction with methadone, and even more so with benzodiazepines (BDZ), which is highly abused among MMT patients, we did a cross sectional studied all 303 patients (February, 2007).

Methods:

Evidence of tricyclics presence in one of the 2±0.5 random urine samples (range1-4) that are routinely taken for opiates, cocaine BDZ, amphetamines, and cannabis. Modified addiction severity index (ASI) and variables from patients’ records.

Results:

48(15.8%) were positive for amitriptyline. They were similar to the others in age, gender, presence of DSM-IV psychiatric disorders, and QTc interval on ECG. Logistic regression (multivariate analyses) found that the extent of being amitriptyline positive was higher in BDZ abusers (OR=11.6 95%CI 4.4-30.7), in subjects with positive antibody to hepatitis C (OR=2.2, 95%CI 1.02-4.9) and in patients treated with high dose methadone (>150 mg/day) (OR=2.4, 95%CI 1.2-4.9). Amitriptyline was found in 12 (7.5%) of the “privileged” group members who, by definition, should not be abusing drugs.

Conclusion:

The high prevalence of amitriptyline abuse, even among “privileged” patients, and in combination with BDZ abuse, emphasizes the importance of routine monitoring in order to decrease the potential risk associated with amitriptyline combined with methadone and BDZ, and to implement appropriate interventions.

Type
Poster Session II: Depression
Copyright
Copyright © European Psychiatric Association 2008
Submit a response

Comments

No Comments have been published for this article.